Novo offers detailed look at semaglutide’s cardiac outcomes in Phase 3 trial as it tees up resubmission
LONDON — After a recent spate of setbacks, Novo Nordisk has raised the curtain on data detailing semaglutide’s ability to cut the risk of heart failure …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
